A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects with Advanced Solid Tumors
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Biosplice Therapeutics, Inc
Start Date
August 25, 2021
End Date
November 29, 2026
Administered By
Duke Cancer Institute
Awarded By
Biosplice Therapeutics, Inc
Start Date
August 25, 2021
End Date
November 29, 2026